Literature DB >> 26130511

Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?

Matthew A Lunning1, James O Armitage2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26130511      PMCID： PMC4486218          DOI： 10.3324/haematol.2015.129924

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.

Authors: 
Journal:  Blood       Date:  1997-06-01       Impact factor: 22.113

2.  Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.

Authors: 
Journal:  Clin Adv Hematol Oncol       Date:  2014-08

3.  How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience.

Authors:  Bin-Tao Huang; Qing-Chun Zeng; Jessica Yu; Zhen Xiao; Bing-Sheng Li; Chun-Lai Zhang; Hong-Bo Ji
Journal:  J Cancer Res Clin Oncol       Date:  2011-11-06       Impact factor: 4.553

4.  Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.

Authors:  Kirit M Ardeshna; Wendi Qian; Paul Smith; Nivette Braganca; Lisa Lowry; Pip Patrick; June Warden; Lindsey Stevens; Christopher F E Pocock; Fiona Miall; David Cunningham; John Davies; Andrew Jack; Richard Stephens; Jan Walewski; Burhan Ferhanoglu; Ken Bradstock; David C Linch
Journal:  Lancet Oncol       Date:  2014-03-04       Impact factor: 41.316

5.  Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.

Authors:  Michael Pfreundschuh; Viola Poeschel; Samira Zeynalova; Mathias Hänel; Gerhard Held; Norbert Schmitz; Andreas Viardot; Martin H Dreyling; Michael Hallek; Carsten Mueller; Martin H J Wiesen; Mathias Witzens-Harig; Lorenz Truemper; Ulrich Keller; Tanja Rixecker; Carsten Zwick; Niels Murawski
Journal:  J Clin Oncol       Date:  2014-11-17       Impact factor: 44.544

6.  Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Authors:  Gilles Salles; John Francis Seymour; Fritz Offner; Armando López-Guillermo; David Belada; Luc Xerri; Pierre Feugier; Réda Bouabdallah; John Vincent Catalano; Pauline Brice; Dolores Caballero; Corinne Haioun; Lars Moller Pedersen; Alain Delmer; David Simpson; Sirpa Leppa; Pierre Soubeyran; Anton Hagenbeek; Olivier Casasnovas; Tanin Intragumtornchai; Christophe Fermé; Maria Gomes da Silva; Catherine Sebban; Andrew Lister; Jane A Estell; Gustavo Milone; Anne Sonet; Myriam Mendila; Bertrand Coiffier; Hervé Tilly
Journal:  Lancet       Date:  2010-12-20       Impact factor: 79.321

7.  Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial.

Authors:  Ulrich Jaeger; Marek Trneny; Helen Melzer; Michael Praxmarer; Weerasak Nawarawong; Dina Ben Yehuda; David Goldstein; Bilijana Mihaljevic; Osman Ilhan; Veronika Ballova; Michael Hedenus; Liang-Tsai Hsiao; Wing-Yan Au; Sonja Burgstaller; Gerhard Weidinger; Felix Keil; Christian Dittrich; Cathrin Skrabs; Anton Klingler; Andreas Chott; Michael A Fridrik; Richard Greil
Journal:  Haematologica       Date:  2015-04-24       Impact factor: 9.941

8.  Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.

Authors:  Michele Ghielmini; Shu-Fang Hsu Schmitz; Sergio B Cogliatti; Gabriella Pichert; Jörg Hummerjohann; Ursula Waltzer; Martin F Fey; Daniel C Betticher; Giovanni Martinelli; Fedro Peccatori; Urs Hess; Emanuele Zucca; Roger Stupp; Tibor Kovacsovics; Claudine Helg; Andreas Lohri; Mario Bargetzi; Daniel Vorobiof; Thomas Cerny
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

9.  Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.

Authors:  Umberto Vitolo; Marco Ladetto; Carola Boccomini; Luca Baldini; Federico De Angelis; Alessandra Tucci; Barbara Botto; Annalisa Chiappella; Annalisa Chiarenza; Antonello Pinto; Amalia De Renzo; Francesco Zaja; Claudia Castellino; Alessia Bari; Isabel Alvarez De Celis; Andrea Evangelista; Guido Parvis; Enrica Gamba; Chiara Lobetti-Bodoni; Giovannino Ciccone; Giuseppe Rossi
Journal:  J Clin Oncol       Date:  2013-08-19       Impact factor: 44.544

10.  Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study.

Authors:  Howard Hochster; Edie Weller; Randy D Gascoyne; Thomas M Habermann; Leo I Gordon; Theresa Ryan; Lijun Zhang; Natalia Colocci; Stanley Frankel; Sandra J Horning
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544
View more
  1 in total

1.  Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis.

Authors:  Divi Cornec; Brian F Kabat; John R Mills; Melissa Cheu; Amber M Hummel; Darrell R Schroeder; Matthew D Cascino; Paul Brunetta; David L Murray; Melissa R Snyder; Fernando Fervenza; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert F Spiera; E William St Clair; John H Stone; David R Barnidge; Ulrich Specks
Journal:  Rheumatology (Oxford)       Date:  2018-04-01       Impact factor: 7.580
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.